The IL-6 hypothesis in COVID-19: A phase 2, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of free IL-6 sequestration by the monoclonal antibody sirukumab in severe and critical COVID-19
In critical COVID-19 patients who received sirukumab, there was no statistically significant difference in time to sustained clinical improvement versus placebo despite objective sequestration of circulating IL-6, questioning IL-6 as a key therapeutic target in COVID-19.
Authors
- Magda Opsomer
- Robert Gottlieb (ORCID: https://orcid.org/0000-0001-8376-8709)
- Meredith E. Clement (ORCID: https://orcid.org/0000-0002-0283-6368)
- Liesbeth Van Wesenbeeck (ORCID: https://orcid.org/0000-0002-1760-9854)
- Philip A. Robinson (ORCID: https://orcid.org/0000-0002-0577-3147)
- Sandra De Meyer (ORCID: https://orcid.org/0000-0001-5524-7324)
- Inge Verbrugge (ORCID: https://orcid.org/0000-0003-4298-061X)
- Yanli Zhuang (ORCID: https://orcid.org/0000-0003-4700-5207)
- Erika Van Landuyt
- Jason W. Chien (ORCID: https://orcid.org/0009-0005-4296-5171)
- Jihad Slim (ORCID: https://orcid.org/0000-0002-4192-7246)
- Audra Deveikis
- Annemie Buelens (ORCID: https://orcid.org/0009-0002-0216-348X)
- Katleen Callewaert
- Cedric W. Spak (ORCID: https://orcid.org/0000-0002-3916-0998)
- Kap Sum Foong (ORCID: https://orcid.org/0000-0001-6259-0032)
- Paul Cook
- Wai Ling Mo
Institutions
- Texas A&M Health Science Center (US)
- Tufts Medical Center (US)
- Hoag Memorial Hospital Presbyterian (US)
- Janssen (Belgium) (BE)
- New York Medical College (US)
- East Carolina University (US)
- MemorialCare Long Beach Medical Center (US)
- University Medical Center New Orleans (US)
- Baylor University Medical Center (US)
- Janssen (United Kingdom) (GB)
- Miller Children's & Women's Hospital (US)
- Janssen (United States) (US)
- Baylor Scott & White Health (US)
- Baylor Scott & White All Saints Medical Center (US)
- Louisiana State University Health Sciences Center New Orleans (US)
Publication Details
- Journal
- Journal of Infection
- Published
- 2024-09-02
- DOI
- https://doi.org/10.1016/j.jinf.2024.106241
- Citations
- 5
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.95
Funders
- Janssen Research and Development